PublisherBMJ Publishing Group
MetadataShow full item record
DescriptionSubtitle: Why they must help us improve the evidence base; Editorial in which the authors discuss drug clinical trial data submitted to the US Food and Drug Administration and call for regulators to correct misleading information published in the medical literature.
CitationDoshi, P. & Godlee, F. (2017). The wider role of regulatory scientists. BMJ, 357. DOI: 10.1136/bmj.j1991
Keywordethical responsibility of regulatory scientists
Access to Information
Clinical Trials as Topic
United States. Food and Drug Administration--ethics
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/6593
- FDA approval of paroxetine for menopausal hot flushes.
- Authors: Orleans RJ, Li L, Kim MJ, Guo J, Sobhan M, Soule L, Joffe HV
- Issue date: 2014 May 8
- Precautionary harm disclosure in clinical trials.
- Authors: Wu KC
- Issue date: 2009 Aug
- COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages.
- Authors: Voloshyna I, Kasselman LJ, Carsons SE, Littlefield MJ, Gomolin IH, De Leon J, Reiss AB
- Issue date: 2017 Mar
- Some key points emerging from the COX-2 controversy.
- Authors: Urquhart J
- Issue date: 2005 Mar
- Lack of Small Intestinal Dysbiosis Following Long-Term Selective Inhibition of Cyclooxygenase-2 by Rofecoxib in the Rat.
- Authors: Lázár B, Brenner GB, Makkos A, Balogh M, László SB, Al-Khrasani M, Hutka B, Bató E, Ostorházi E, Juhász J, Kemény Á, László T, Tiszlavicz L, Bihari Z, Giricz Z, Szabó D, Helyes Z, Ferdinandy P, Gyires K, Zádori ZS
- Issue date: 2019 Mar 15